Annex 4Declarations of Interest

Publication Details

Declarations of Interest.

Table

Declarations of Interest.

Declarations of Interest.

Table

Declarations of Interest.

Declarations of Interest.

Table

Declarations of Interest.

Declarations of Interest.

Table

Declarations of Interest.

Declarations of Interest.

Table

Declarations of Interest.

Publication Details

Copyright

Copyright © World Health Organization 2013.

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html).

Publisher

World Health Organization, Geneva

NLM Citation

The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva: World Health Organization; 2013. Annex 4, Declarations of Interest.

Declarations of Interest

Expert Group meeting on interim advice for the use of bedaquiline in the treatment of MDR-TB None declared
Elie Akl	Richard E. Chaisson	Michael L. Rich
Adekunle Victor Babawele	Ms Lucy Chesire	Simon Schaaf
Mauricio Baretto	Norbert Ndjeka	Holger Schünemann
Dr Martien W. Borgdorff	Nguyen Viet Nhung	Francis Varaine
Erlina Burhan		Susan Van Den Hof
		Piret Viiklepp

Declarations of Interest

Expert Group meeting on interim advice for the use of bedaquiline in the treatment of MDR-TB Declared: insignificant
Andrew Vernon	Supervises a branch at CDC that supports a consortium conducting clinical trials in TB that receives modest support (e.g., drug supplies for studies) from several manufacturers. One company, Sanofi-Aventis, has provided $1.7 million to the CDC Foundation to support work on rifapentine. Neither I nor any of my staff has received any personal benefit from these funds.

Declarations of Interest

Expert Group meeting on interim advice for the use of bedaquiline in the treatment of MDR-TB
Declared: insignificant

Erica Lessem

TAG's TB/HIV Project receives funding from the Bill & Melinda Gates Foundation to conduct advocacy to accelerate research and development into new tools to fight TB and TB/HIV coinfection, and to promote universal access to effective tools and services. Activities supported by this funding include TB/HIV Project team operations, participation in meetings with key researchers and policymakers, attendance to scientific conferences, writing publications such as the Pipeline Report which provides an overview of all new drugs, diagnostics and vaccines in the pipeline for TB and other diseases, and coordinating a global TB community advisory board which provides input in the development and roll-out of tools to fight TB.
In addition, TAG's Hepatitis C program received from Janssen Therapeutics/Tibotec Therapeutics $10,000/year in 2011 and 2012 (not for any of my word or the TB/HIV project)

Declarations of Interest

Expert Group meeting on interim advice for the use of bedaquiline in the treatment of MDR-TB Technical Resource Persons – None declared
Bernard Fourie Ekaterina Kurbatova	Charles Peloquin	Anna Vassall

Declarations of Interest

Expert Group meeting on interim advice for the use of bedaquiline in the treatment of MDR-TB Observers
Xiumin Huo	Chief Pharmacist, State Food and Drug Administration, Beijing, China
Mukadi Ya-Diul	Works for a funding organization supporting drug research and development